List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 312 studies with search of: "Sorafenib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Condition: Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Interventions: Drug: sorafenib;   Drug: sorafenib;   Drug: sorafenib and cisplatin;   Drug: sorafenib and cisplatin;   Drug: sorafenib and cisplatin
2 Recruiting Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib and Ixabepilone;   Drug: Sorafenib and Ixabepilone
3 Active, not recruiting Sorafenib Gastric Cancer Asian Phase I Study
Condition: Gastric Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006)
4 Recruiting Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
Condition: Refractory Malignancy
Interventions: Drug: Capecitabine and Sorafenib;   Drug: Capecitabine and Sorafenib
5 Completed Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
Conditions: Metastatic Disease;   Renal Cell Carcinoma
Interventions: Drug: Nexavar (Sorafenib);   Drug: IL-2
6 Recruiting A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006)
7 Active, not recruiting Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)
Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: sorafenib
8 Recruiting Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Sorafenib and Erlotinib;   Drug: Sorafenib
9 Completed Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: CP-4055;   Drug: Sorafenib (Nexavar)
10 Recruiting Sorafenib/Carboplatin/Paclitaxel in Patients With Solid Tumors
Condition: Cancer
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
11 Recruiting A 3rd/4th Line Placebo-Controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
12 Not yet recruiting Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatoma
Interventions: Drug: sorafenib;   Procedure: LC Bead-TACE
13 Recruiting Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
Conditions: AML;   Acute Myeloid Leukemia;   Myelodysplastic Disorders
Interventions: Drug: Idarubicin;   Drug: sorafenib;   Drug: Ara-C
14 Recruiting XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: AEG35156 antisense IV infusion;   Drug: Sorafenib
15 Recruiting Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
Conditions: Melanoma Stage III or IV;   No Prior Chemotherapy
Intervention: Drug: Sorafenib (Nexavar), Dacarbazine (DTIC)
16 Recruiting Sorafenib Long Term Extension Program (STEP)
Condition: Cancer
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
17 Completed A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonäive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Paclitaxel/ Carboplatin
18 Recruiting Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
19 Recruiting Sorafenib/Docetaxel Dose Escalation Trial
Condition: Cancer
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
20 Recruiting Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: oral vinorelbine;   Drug: sorafenib

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services